Pharmacological characterization of glutamatergic agonists and antagonists at recombinant human homomeric and heteromeric kainate receptors in vitro. 2004

A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
Lilly Research Laboratories, Eli Lilly and Company, Neuroscience Discovery Research, Lilly Corporate Center, Indianapolis, IN 46285, USA. alt_andrew_jason@lilly.com

An increasing body of evidence suggests that native kainate receptors form ion channels from homomeric and heteromeric combinations of five receptor subunits: GluR5, GluR6, GluR7, KA1 and KA2. We have examined the activity of agonists and antagonists at recombinant human kainate receptors expressed in HEK293 cells, using both whole-cell electrophysiological recording and 96-well plate fluo-3 based calcium microfluorimetry (FLIPR). Both homomeric (GluR5 and GluR6) and heteromeric (GluR5/6, GluR5/KA2 and GluR6/KA2) receptors were examined. Heteromeric receptor assemblies showed electrophysiological and pharmacological profiles which were distinct from homomeric channels. Several agonists, including AMPA, ATPA and (S)-5-iodowillardiine, and antagonists, including gamma-D-glutamylaminomethylsulphonic acid (GAMS) and the decahydroisoquinoline compounds LY293558, LY377770 and LY382884, were found to act at GluR5-containing channels while having no effect at GluR6 homomers. AMPA, ATPA and (S)-5-iodowillardiine did activate GluR6/KA2 heteromers, but only as partial agonists. Additionally, ATPA was shown to act as an antagonist at homomeric GluR6 receptors at high concentrations (IC50 approximately 2 mM). Kynurenic acid was also found to differentiate between GluR6 and GluR6/KA2 receptors, antagonizing glutamate at GluR6 (IC50 = 0.4 mM), while having no effect at GluR6/KA2 channels. The results of the current study provide a broad pharmacological characterization of both homomeric and heteromeric recombinant human kainate receptors, and identify which compounds are likely to be useful tools for studying these various receptor subtypes.

UI MeSH Term Description Entries
D008564 Membrane Potentials The voltage differences across a membrane. For cellular membranes they are computed by subtracting the voltage measured outside the membrane from the voltage measured inside the membrane. They result from differences of inside versus outside concentration of potassium, sodium, chloride, and other ions across cells' or ORGANELLES membranes. For excitable cells, the resting membrane potentials range between -30 and -100 millivolts. Physical, chemical, or electrical stimuli can make a membrane potential more negative (hyperpolarization), or less negative (depolarization). Resting Potentials,Transmembrane Potentials,Delta Psi,Resting Membrane Potential,Transmembrane Electrical Potential Difference,Transmembrane Potential Difference,Difference, Transmembrane Potential,Differences, Transmembrane Potential,Membrane Potential,Membrane Potential, Resting,Membrane Potentials, Resting,Potential Difference, Transmembrane,Potential Differences, Transmembrane,Potential, Membrane,Potential, Resting,Potential, Transmembrane,Potentials, Membrane,Potentials, Resting,Potentials, Transmembrane,Resting Membrane Potentials,Resting Potential,Transmembrane Potential,Transmembrane Potential Differences
D009474 Neurons The basic cellular units of nervous tissue. Each neuron consists of a body, an axon, and dendrites. Their purpose is to receive, conduct, and transmit impulses in the NERVOUS SYSTEM. Nerve Cells,Cell, Nerve,Cells, Nerve,Nerve Cell,Neuron
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D017470 Receptors, Glutamate Cell-surface proteins that bind glutamate and trigger changes which influence the behavior of cells. Glutamate receptors include ionotropic receptors (AMPA, kainate, and N-methyl-D-aspartate receptors), which directly control ion channels, and metabotropic receptors which act through second messenger systems. Glutamate receptors are the most common mediators of fast excitatory synaptic transmission in the central nervous system. They have also been implicated in the mechanisms of memory and of many diseases. Excitatory Amino Acid Receptors,Glutamate Receptors,Receptors, Excitatory Amino Acid,Excitatory Amino Acid Receptor,Glutamate Receptor,Receptor, Glutamate
D051381 Rats The common name for the genus Rattus. Rattus,Rats, Laboratory,Rats, Norway,Rattus norvegicus,Laboratory Rat,Laboratory Rats,Norway Rat,Norway Rats,Rat,Rat, Laboratory,Rat, Norway,norvegicus, Rattus
D018092 Receptors, Kainic Acid A class of ionotropic glutamate receptors characterized by their affinity for KAINIC ACID. Kainate Receptors,Kainic Acid Receptors,Receptors, Kainate,Kainate Receptor,Kainic Acid Receptor,Receptor, Kainate,Receptor, Kainic Acid

Related Publications

A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
October 2014, Neuroscience,
A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
October 2013, The Journal of physiology,
A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
March 2003, British journal of pharmacology,
A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
November 1998, European journal of pharmacology,
A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
August 2001, Neuropharmacology,
A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
October 2012, ChemMedChem,
A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
March 2019, Neurochemical research,
A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
April 2002, Mini reviews in medicinal chemistry,
A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
September 2007, Life sciences,
A Alt, and B Weiss, and A M Ogden, and J L Knauss, and J Oler, and K Ho, and T H Large, and D Bleakman
May 2019, Scientific reports,
Copied contents to your clipboard!